01—Abstract
Summary
Summary of the 10-Q filed August 31, 2023. Cited figures are marked; the original filing is the authoritative source.
Medtronic plc reported solid revenue growth for the first quarter of fiscal year 2024, with net sales increasing by 5% year-over-year to $7.7 billiona.
This growth was primarily driven by strong performance across its Cardiovascular and Neuroscience segments, with notable contributions from key products like Micra, TAVR systems, and Spine & Biologics. Diluted earnings per share (EPS) saw a decrease to $0.59b from $0.70 in the prior year period, impacted by a significant $187 million income tax charge related to an Israeli court decision, among other factors. The company maintained a strong liquidity position with $1.3 billion in cash and cash equivalents.
Despite facing ongoing macroeconomic challenges, including inflation and supply chain pressures, Medtronic demonstrated resilience and strategic progress, including a pending acquisition of EOFlow to bolster its Diabetes segment. Key financial highlights include a 5% increase in total net sales to $7.7 billionc, with the Cardiovascular segment leading growth at 6% and Neuroscience at 5%. The company also reported a 6% increase in Medical Surgical sales and a 7% increase in Diabetes sales, signaling broad-based demand.
Free cash flow remained robust at $521 milliond, underscoring operational efficiency. However, investors should note the decrease in EPS and the increased effective tax rate primarily due to the aforementioned tax charge, which temporarily impacted profitability. Medtronic continues to invest in innovation and strategically expand its product portfolio.
02—Key points
Key Highlights
- Net sales increased by 5% to $7.7 billion, driven by broad-based growth across segments, particularly Cardiovascular and Neuroscience.
- Diluted Earnings Per Share (EPS) decreased to $0.59 from $0.70 in the prior year, significantly impacted by a $187 million income tax charge related to an Israeli court decision.
- Cardiovascular segment sales grew 6% to $2.9 billion, led by strong performance in Micra, TAVR systems, and Coronary & Peripheral Vascular products.
- Neuroscience segment sales rose 5% to $2.2 billion, supported by growth in Spine & Biologics, Neurosurgery, and ENT.
- Free cash flow remained strong at $521 million, indicating healthy operational cash generation.
- Medtronic is pursuing the acquisition of EOFlow for approximately $760 million to expand its Diabetes segment offerings.
- The company reported a higher effective tax rate of 33.4% compared to 10.7% in the prior year, largely due to the tax charge and other adjustments.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, Medtronic plc kept $0.10.
- Revenue$7.70B100.0%
- Cost of revenue−$2.63B34.1%
- Gross profit$5.07B65.9%
- Operating costs−$3.81B49.4%
- Operating income$1.27B16.5%
- Interest, other & tax−$471.0M6.1%
- Net income$797.0M10.3%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed August 31, 2023Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $7.70B$7.37B | +4.5% |
| Cost of Revenue | $2.63B$2.52B | +4.5% |
| Gross Profit | $5.07B$4.86B | +4.5% |
| SG&A Expenses | $2.61B$2.57B | +1.8% |
| Operating Income | $1.27B$1.13B | +12.7% |
| Interest Expense | $148.00M$164.00M | −9.8% |
| Net Income | $797.00M$931.00M | −14.4% |
| EPS (Basic) | $0.59$0.70 | −15.7% |
| EPS (Diluted) | $0.59$0.70 | −15.7% |
| Shares Outstanding (Basic) | 1.33B1.33B | +0.1% |
| Shares Outstanding (Diluted) | 1.33B1.33B | −0.1% |
05—Questions
Frequently Asked Questions
What was the primary driver behind Medtronic's revenue growth in this quarter?
Medtronic's revenue growth was primarily driven by strong performance across its key segments, particularly Cardiovascular and Neuroscience. Specific product lines like Micra, TAVR systems, Spine & Biologics, and Advanced Energy contributed significantly to the 5% increase in net sales year-over-year.
Why did Medtronic's earnings per share (EPS) decrease compared to the previous year?
The decrease in diluted EPS from $0.70 to $0.59 was significantly influenced by a $187 million income tax charge stemming from an Israeli court decision concerning intellectual property transfer. Additionally, other non-GAAP adjustments and changes in tax rates also contributed to the lower EPS.
How is Medtronic managing supply chain and inflationary pressures?
Medtronic is actively managing cost of production through supplier management, manufacturing improvements, and optimizing its manufacturing network. The company also continues to monitor and adapt to macroeconomic factors like inflation and supply chain challenges, aiming to mitigate their impact on profitability and operations.
What is the outlook for Medtronic's key growth drivers in the coming quarters?
Medtronic expects continued growth from its Cardiovascular segment, driven by advancements in its Micra pacing systems and TAVR technology. The Neuroscience segment anticipates continued adoption of integrated solutions like the Aible offering. The Diabetes segment is poised for growth with the planned acquisition of EOFlow and continued expansion of its MiniMed 780G insulin pump system.
06—Continue